Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
2,093 articles
📰
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +586.28% and +300.65%, respectively, for the quarter ended December 2025. Do...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Dermata Therapeutics (NASDAQ:DRMA) stock rose 14.0% to $1.38 during Thursday's after-market session. The company's market cap...
Firefly Stock Jumps On Better-Than-Expected Q4 Results
Firefly Aerospace Inc (NASDAQ:FLY) reported financial results for the fourth quarter after the market close on Thursday. Here’s a look at the...
Planet Labs Stock Drives Higher After Q4 Beats Estimates
Planet Labs PBC (NYSE:PL) shares drove higher in Thursday's extended trading after the company released its fourth-quarter earnings...
📰
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --
-- Interim systemic lung cancer...
📰
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer...
📰
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated...
📰
Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated...
📰
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong...
📰
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
REGULATED INFORMATION
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
U.S. Commercialization Off to a Strong Start...
📰
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80...
📰
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S....
📰
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80...
📰
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179,...
📰
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety...
📰
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety...
📰
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S....
📰
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to...
📰
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
Final Data from Phase 2 Expansion...
📰
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully...
📰
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NUC-7738 Demonstrates Clinical Activity and Favorable Safety in Patients with PD-1 Inhibitor-Resistant Melanoma
📰
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully...
📰
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.